The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease. (15th August 2019)

• Record Type: Journal Article
• Authors: Mayer, Otto; Seidlerová, Jitka; Černá, Václava; Kučerová, Alena; Vaněk, Jiří; Karnosová, Petra; Bruthans, Jan; Wohlfahrt, Peter; Cífková, Renata; Pešta, Martin; Filipovský, Jan
• Is Part Of: International journal of cardiology. Volume 289(2019)
• Page Start: 101
• Page End: 106
• Publication Date: 2019-08-15
• Subjects: Micro-ribonucleic acids (miRNAs) -- Atherosclerotic disease -- Secondary prevention -- Risk prediction -- EUROASPIRE; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2019.05.008
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Secondary prevention of atherosclerotic vascular diseases represents a cascade of procedures to reduce the risk of future fatal and non-fatal cardiovascular events. We sought to determine whether the expression of selected microRNAs influenced mortality of stable chronic cardiovascular patients. Methods: The plasma concentrations of five selected microRNAs (miR-1, miR-19, miR-126, miR-133 and miR-223) were quantified in 826 patients (mean age 65.2 years) with stable vascular disease (6–36 months after acute coronary syndrome, coronary revascularization or first-ever ischemic stroke). All-cause and cardiovascular mortality rates were followed during our prospective study. Results: Low expression (bottom quartile) of all five miRNAs was associated with a significant increase in five-year all-cause death, even when adjusted for conventional risk factors, treatment, raised troponin I and brain natriuretic protein levels [hazard risk ratios (HRRs) were as follows: miR-1, 1.65 (95% CI: 1.16–2.35); miR-19a, 2.27 (95% CI: 1.59–3.23); miR-126, 1.64 (95% CI: 1.15–2.33); miR-133a, 1.46 (95% CI: 1.01–2.12) and miR-223, 2.05 (95% CI: 1.45–2.91)]. Nearly similar results were found if using five-year cardiovascular mortality as the outcome. However, if entering all five miRNAs (along with other covariates) into a single regression model, only low miR-19a remained a significant mortality predictor; and only in patients with coronary artery disease [3.00 (95% CI: 1.77–5.08)], but not in post-stroke patients [1.63 (95% CI: 0.94–2.86)]. Conclusions: In stable chronic coronary artery disease patients, low miR-19a expression was associated with a substantial increase in mortality risk independently of other conventional cardiovascular risk factors. Highlights: Circulating miRNA's estimation may improve risk prediction in coronary patients. Low miR-19a expression indicated about 4× higher cardiovascular mortality risk. This phenomenon reflects probably impaired reparation potential of cardiomyocytes.